These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15833062)

  • 1. Inhibitors of the mammalian target of rapamycin.
    Dancey JE
    Expert Opin Investig Drugs; 2005 Mar; 14(3):313-28. PubMed ID: 15833062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targets: MTOR and related pathways.
    Dancey JE
    Cancer Biol Ther; 2006 Sep; 5(9):1065-73. PubMed ID: 16969122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future.
    MacKenzie AR; von Mehren M
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1145-54. PubMed ID: 18028023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR inhibitors in the treatment of cancer.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2008 Nov; 17(11):1717-34. PubMed ID: 18922108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
    Bjelogrlić SK; Srdić T; Radulović S
    J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
    Wysocki PJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway.
    Smolewski P
    Anticancer Drugs; 2006 Jun; 17(5):487-94. PubMed ID: 16702804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.
    Mita M; Sankhala K; Abdel-Karim I; Mita A; Giles F
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1947-54. PubMed ID: 19012509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma.
    Reddy GK; Mughal TI; Rini BI
    Clin Genitourin Cancer; 2006 Sep; 5(2):110-3. PubMed ID: 17026798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.
    Teachey DT; Grupp SA; Brown VI
    Br J Haematol; 2009 Jun; 145(5):569-80. PubMed ID: 19344392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biology behind mTOR inhibition in sarcoma.
    Wan X; Helman LJ
    Oncologist; 2007 Aug; 12(8):1007-18. PubMed ID: 17766661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Everolimus (RAD001) and solid tumours: a 2008 summary].
    Lévy A; Sauvin LA; Massard C; Soria JC
    Bull Cancer; 2008 Dec; 95(12):1205-11. PubMed ID: 19091655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development of mTOR inhibitors: a focus on lymphoma.
    Smith SM
    Rev Recent Clin Trials; 2007 May; 2(2):103-10. PubMed ID: 18473994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current development of mTOR inhibitors as anticancer agents.
    Faivre S; Kroemer G; Raymond E
    Nat Rev Drug Discov; 2006 Aug; 5(8):671-88. PubMed ID: 16883305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The applicability of mTOR inhibition in solid tumors.
    Konings IR; Verweij J; Wiemer EA; Sleijfer S
    Curr Cancer Drug Targets; 2009 May; 9(3):439-50. PubMed ID: 19442061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of targeting mammalian target of rapamycin in lung cancer.
    Pal SK; Figlin RA; Reckamp KL
    Clin Lung Cancer; 2008 Nov; 9(6):340-5. PubMed ID: 19073516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.